Tempus AI earnings release, May 5, 2026

Tempus AI, Inc. (TEM) · Form 8-K, Item 2.02 · Filed · SEC filing

Tempus Reports First Quarter 2026 Results

CHICAGO, May 5, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026.

• Revenue of $348.1 million, up 36.1% year-over-year

• Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28%

• MRD volume was ~6,500 tests in Q1 2026, up ~500% year-over-year

• Data and Applications revenue of $87.0 million, representing 40.5% year-over-year growth, with Insights (data licensing and modeling) growing 44.1%

• $643.8 million in cash and marketable securities as of March 31, 2026

• Increasing revenue guidance to $1.59 to $1.60 billion for 2026 and expect full year 2026 Adjusted EBITDA of approximately $65 million

“Our strong financial and operational performance this quarter underscores the accelerating demand for our AI-driven diagnostic platform and the immense value of our multimodal data and corresponding AI models,” said Eric Lefkofsky, Founder and CEO of Tempus. “We continue to see strong momentum as we deploy more sophisticated algorithms across our platform, driving 36% revenue growth year-over-year, with particular strength in our Oncology diagnostic business and data and modeling business”.

First Quarter Summary Results

• Revenue increased 36.1% year-over-year to $348.1 million.

• Diagnostics generated $261.1 million of revenue, representing 34.7% year-over-year growth, driven by Oncology volume growth of 28% and Hereditary volume growth of 54% (7% growth when accounting for Ambry's 2025 pre-acquisition volumes given February's closing date).

• Data and Applications revenue generated $87.0 million of revenue, representing 40.5% year-over-year growth, with Insights growing 44.1%.

• Gross profit increased 43.1% year-over-year to $222.0 million, led by growth in Data and Applications.

• Net loss was ($125.9 million), which included $56.3 million of stock compensation expense and related employer payroll taxes in the first quarter and $32.3 million in unrealized losses on marketable securities, compared to a net loss of ($68.0 million) in the first quarter of 2025 and a net loss of ($54.2 million) in the fourth quarter of 2025.

• Adjusted EBITDA was ($2.8 million), compared to ($16.2 million) in the first quarter of 2025 and $12.9 million in the fourth quarter of 2025.

Recent Operational Highlights

• Established a multi-year, strategic collaboration with Merck to accelerate biomarker discovery and development by leveraging Tempus’ multimodal data and Lens analytical platform.

• Expanded our collaboration with Gilead to provide enterprise-wide access to our AI-driven Lens platform and multimodal datasets, aimed at advancing their oncology pipeline through real-world evidence and AI-driven insights.

• Selected by Northwestern Medicine to expand genomic testing access to oncology patients across the health system, leveraging Tempus' full suite of DNA, RNA, liquid biopsy, and MRD tests to enable more personalized cancer care and clinical trial design.

• Entered a multi-year strategic collaboration with NYU Langone Health, centered on a prospective observational study that uses serial molecular profiling to track cancer evolution and treatment resistance, with the goal of developing AI-powered diagnostic tools and personalized therapies.

• Entered strategic collaboration with Blood Cancer United to develop one of the largest real-world data registries for pediatric acute myeloid leukemia, aimed at accelerating research and improving treatment options for young patients.

• Announced study results from the ALERT trial in collaboration with Medtronic showing that Tempus’ AI-driven EHR notifications increased life-saving heart valve procedures by 40% for patients with significant disease.

• Published a study in JCO Precision Oncology demonstrating that Tempus' advanced features including tumor-normal matching and RNA sequencing identified actionable findings in 12% of patients that were missed by standard testing.

• Announced the launch of a first-of-its-kind pan-cancer algorithm that utilizes RNA expression data to identify Homologous Recombination Deficiency (HRD), expanding the number of patients who may benefit from PARP inhibitors beyond those identified by traditional DNA testing.

First Quarter Financial Results

Financial Outlook and Guidance

Tempus is increasing full year 2026 revenue guidance to $1.59 billion - $1.60 billion, which represents ~25% annual growth. We continue to expect 2026 Adjusted EBITDA to be ~$65 million.

For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com.

Webcast and Conference Call Information

A conference call and webcast will begin today, May 5, 2026 after market close at 4:30 p.m. Eastern Time. Interested parties may access details at:

Conference ID: 4294068

Domestic Dial-in Number: (646) 307-1963

International Dial-in Number: (800) 715-9871

Live webcast: https://edge.media-server.com/mmc/p/rv7jv7ti

The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO and Jim Rogers, CFO, which will be discussed on the conference call and webcast.

Tempus Inaugural Investor Day and Webcast Details

Tempus will host its inaugural Investor Day for analysts and institutional investors on Friday, May 29, 2026.... (truncated)e company's Diagnostics and Data & Applications organizations. The live webcast of management presentations is scheduled to begin at 8:00 a.m. Central Time.

The Investor Day will be broadcast live and can be accessed through the Investor Relations section of the Tempus website under the “News & Events” tab at investors.tempus.com. Institutional investors can request in-person attendance at our Chicago headquarters by emailing investorrelations@tempus.com.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Non-GAAP Financial Measures

In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Tempus also presents adjusted non-GAAP financial measures.

Non-GAAP gross profit is defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the “stock-based compensation adjustments”).

Non-GAAP gross margin is defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue.

Non-GAAP operating expenses are calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments, acquisition-related expenses, and amortization of intangibles due to acquisition.

Non-GAAP loss from operations is defined as loss from operations, adjusted to exclude (i) the stock-based compensation adjustments, (ii) acquisition-related expenses, and (iii) amortization of intangibles due to acquisition.

Non-GAAP net loss is defined as net loss, adjusted to exclude (i) changes in fair value of our marketable equity securities and indemnity-related holdback liabilities, (ii) the stock-based compensation adjustments, (iii) acquisition-related expenses, (iv) amortization of intangibles due to acquisition, (v) losses from equity method investments, (vi) benefit from income taxes, and (vii) amortization of deferred other income from our IP License Agreement with SB Tempus.

Non-GAAP net loss per share is defined as non-GAAP net loss divided by weighted average common shares outstanding, basic and diluted.

Adjusted EBITDA is defined as net loss, adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) benefit from income taxes, (v) losses from equity method investments, (vi) changes in fair value of our marketable equity securities and indemnity-related holdback liabilities, (vii) the stock-based compensation adjustments, (viii) acquisition-related expenses, and (ix) amortization of deferred other income from our IP License Agreement with SB Tempus.

Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.

Tempus does not provide guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net loss and the respective reconciliations. These forecasted items are not within Tempus’ control, may vary greatly between periods, and could significantly impact future financial results.

Other Key Metrics

Total Remaining Contract Value (TCV) is equal to the total potential value of signed contracts and assumes the exercise of all contract options, all discretionary opt-ins, and no early termination. Remaining TCV excludes any revenue recognized to date on these contracts or any future adjustments made to the contractual value as a result of amendments or terminations.

Net Revenue Retention compares the annual Insights product revenue generated from all customers that made an Insights purchase in one year to the annual Insights product revenue generated from the same cohort of customers in the subsequent year.

Financial statements

Income Statement

Three Months Ended March 31, — First Quarter Financial Results (in thousands, except percentages and per share amounts)

Three Months Ended March 31, – 2026 – (unaudited)Three Months Ended March 31, – 2025 – (unaudited)Change
Revenue348,116255,73736.1%
Gross profit222,041155,20343.1%
Loss from operations-84,711-68,68923.3%
Non-GAAP loss from operations-11,580-25,777-55.1%
Net loss-125,919-68,03785.1%
Non-GAAP net loss-22,612-41,561-45.6%
Adjusted EBITDA-2,833-16,17482.5%
Net loss per share, basic-0.7-0.475.0%
Non-GAAP net loss per share, basic-0.13-0.24-45.8%

Income Statement

Three Months Ended March 31, — (in thousands, except per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net revenueDiagnostics261,098193,804
Net revenueData and applications(1)87,01861,933
Net revenueTotal net revenue348,116255,737
Cost and operating expensesCost of revenues, diagnostics100,96084,783
Cost and operating expensesCost of revenues, data and applications25,11515,751
Cost and operating expensesTechnology research and development45,92133,391
Cost and operating expensesResearch and development48,23735,874
Cost and operating expensesSelling, general and administrative212,594154,627
Cost and operating expensesTotal cost and operating expenses432,827324,426
Cost and operating expensesLoss from operations-84,711-68,689
Cost and operating expensesInterest income3,8661,813
Cost and operating expensesInterest expense-14,341-18,003
Cost and operating expensesOther expense, net-27,709-27,455
Cost and operating expensesLoss before benefit from income taxes-122,895-112,334
Cost and operating expensesBenefit from income taxes6246,180
Cost and operating expensesLosses from equity method investments-3,086-1,883
Cost and operating expensesNet Loss-125,919-68,037
Net loss per shareBasic-0.7-0.4
Net loss per shareDiluted-0.71-0.4
Weighted-average shares outstanding used to compute net loss per shareBasic178,880170,506
Weighted-average shares outstanding used to compute net loss per shareDiluted178,964170,506
Comprehensive Loss, net of taxNet loss-125,919-68,037
Comprehensive Loss, net of taxForeign currency translation adjustment-1,8104,598
Comprehensive Loss, net of taxComprehensive loss-127,729-63,439

Income Statement

Three Months Ended March 31, — Diagnostics Gross Profit & Gross Margin (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Diagnostics revenue261,098193,804
Cost of revenues, diagnostics100,96084,783
Gross profit, diagnostics160,138109,021
Stock-based compensation expense2,1221,035
Employer payroll tax related to stock-based compensation33448
Non-GAAP gross profit, diagnostics162,594110,104
Diagnostics gross margin61.3%56.3
Stock-based compensation expense0.8%0.5
Employer payroll tax related to stock-based compensation0.1%0
Non-GAAP gross margin, diagnostics62.3%56.8

Income Statement

Three Months Ended March 31, — Data and applications Gross Profit & Gross Margin

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Data and applications revenue87,01861,933
Cost of revenues, data and applications25,11515,751
Gross profit, data and applications61,90346,182
Stock-based compensation expense1,553611
Employer payroll tax related to stock-based compensation18444
Non-GAAP gross profit, data and applications63,64046,837
Gross margin, data and applications71.1%74.6
Stock-based compensation expense1.8%1
Employer payroll tax related to stock-based compensation0.2%0.1
Non-GAAP gross margin, data and applications73.1%75.6

Income Statement

Three Months Ended March 31, — Total Gross Profit & Gross Margin

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net revenue348,116255,737
Cost of revenues126,075100,534
Gross profit222,041155,203
Stock-based compensation expense3,6751,646
Employer payroll tax related to stock-based compensation51891
Non-GAAP gross profit226,234156,940
Gross margin63.8%60.7
Stock-based compensation expense1.1%0.6
Employer payroll tax related to stock-based compensation0.1%0
Non-GAAP gross margin65.0%61.4

Income Statement

Three Months Ended March 31, — Operating Expenses

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Technology research and development45,92133,391
Stock-based compensation expense9,5063,319
Employer payroll tax related to stock-based compensation812261
Non-GAAP technology research and development35,60329,811
Research and development48,23735,874
Stock-based compensation expense4,5651,982
Employer payroll tax related to stock-based compensation483176
Non-GAAP research and development43,18933,716
Selling, general and administrative212,594154,627
Stock-based compensation expense34,96016,027
Employer payroll tax related to stock-based compensation1,7454,725
Acquisition related expenses(1)-43,529
Amortization of intangibles due to acquisition16,87111,156
Non-GAAP selling, general and administrative159,022119,190
Operating expenses306,752223,892
Stock-based compensation expense49,03121,328
Employer payroll tax related to stock-based compensation3,0405,162
Acquisition related expenses(1)-43,529
Amortization of intangibles due to acquisition16,87111,156
Non-GAAP operating expenses237,814182,717

Income Statement

Three Months Ended March 31, — Earnings per Share

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net loss-125,919-68,037
Fair value changes(1)31,14131,850
Stock-based compensation expense52,70622,974
Employer payroll tax related to stock-based compensation3,5585,253
Acquisition related expenses(2)-43,529
Amortization of intangibles due to acquisition16,87111,156
Losses from equity method investments3,0861,883
Benefit from income taxes-62-46,180
Amortization of technology license-3,989-3,989
Non-GAAP net loss-22,612-41,561
Non-GAAP net loss per share, basic-0.13-0.24
Weighted average common shares outstanding, basic178,880170,506

Balance Sheet

March 31, 2026 — (in thousands, except share and per share amounts)

March 31, 2026December 31, 2025
Current AssetsCash and cash equivalents521,170604,787
Current AssetsAccounts receivable(1), net of allowances of $2,872 and $2,755 at March 31, 2026 and December 31, 2025, respectively308,599311,170
Current AssetsInventory51,83151,724
Current AssetsRelated party asset11,9108,785
Current AssetsPrepaid expenses and other current assets42,53040,498
Current AssetsMarketable equity securities117,902150,211
Current AssetsTotal current assets1,053,9421,167,175
Current AssetsProperty and equipment, net88,59389,156
Current AssetsGoodwill470,169470,211
Current AssetsIntangible assets, net330,587349,202
Current AssetsCapitalized software, net9,5056,051
Current AssetsInvestments and other assets20,53021,111
Current AssetsInvestment in joint venture81,67586,557
Current AssetsRelated party asset, less current portion13,09016,215
Current AssetsOperating lease right-of-use assets62,30664,496
Current AssetsRestricted cash4,6944,664
Current AssetsTotal Assets2,135,0912,274,838
Current LiabilitiesAccounts payable41,02381,994
Current LiabilitiesAccrued expenses160,628155,370
Current LiabilitiesDeferred revenue(2)72,86692,673
Current LiabilitiesDeferred other income15,95515,955
Current LiabilitiesOther current liabilities10,2488,680
Current LiabilitiesOperating lease liabilities12,63913,355
Current LiabilitiesAccrued data licensing fees4,5974,361
Current LiabilitiesTotal current liabilities317,956372,388
Current LiabilitiesOperating lease liabilities, less current portion72,72374,272
Current LiabilitiesConvertible promissory note199,279208,672
Current LiabilitiesOther long-term liabilities54,11556,600
Current LiabilitiesRevolving credit facility100,000100,000
Current LiabilitiesInterest payable15,84412,393
Current LiabilitiesLong-term debt, net204,624202,753
Current LiabilitiesConvertible senior notes, net729,267728,078
Current LiabilitiesDeferred other income, less current portion3,9897,977
Current LiabilitiesDeferred revenue, less current portion20,88920,379
Current LiabilitiesTotal Liabilities1,718,6861,783,512

Balance Sheet

(in thousands, except share and per share amounts)

Commitments and contingencies (Note 8)Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively, no shares issued and outstanding at March 31, 2026 and December 31, 2025$—$—
Stockholders' equityClass A Common Stock, $0.0001 par value, 1,000,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; 174,360,831 and 173,235,428 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively1717
Stockholders' equityClass B Common Stock, $0.0001 par value, 5,500,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; 5,043,789 issued and outstanding at March 31, 2026 and December 31, 2025, respectively11
Stockholders' equityTreasury Stock, 183,229 shares at March 31, 2026 and December 31, 2025, respectively, at cost-6,642-6,642
Stockholders' equityAdditional Paid-In Capital2,945,7182,892,910
Stockholders' equityAccumulated Other Comprehensive (Loss) Income-908902
Stockholders' equityAccumulated deficit-2,521,781-2,395,862
Stockholders' equityTotal Stockholders' equity416,405491,326
Stockholders' equityTotal Liabilities, Convertible redeemable preferred stock, and Stockholders' equity2,135,0912,274,838

Balance Sheet

Three Months Ended March 31, — (in thousands, except per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Operating activitiesNet loss-125,919-68,037
Adjustments to reconcile net loss to net cash used in operating activitiesStock-based compensation52,70622,974
Adjustments to reconcile net loss to net cash used in operating activitiesLoss on marketable equity securities32,30931,805
Adjustments to reconcile net loss to net cash used in operating activitiesLoss on disposal of property and equipment334
Adjustments to reconcile net loss to net cash used in operating activitiesDeferred income taxes-46,216
Adjustments to reconcile net loss to net cash used in operating activitiesLosses from equity method investments3,0861,883

Cash Flow

Three Months Ended March 31, — (in thousands, except per share amounts)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Investing activitiesPurchases of property and equipment-8,202-2,074
Investing activitiesProceeds from sale of marketable equity securities8,316
Investing activitiesBusiness combinations, net of cash acquired (Note 4)-380,762
Investing activitiesCapitalized software costs-1,865-1,298
Investing activitiesNet cash used in investing activities-10,067-375,818
Financing activitiesPayment of deferred offering costs-45
Financing activitiesProceeds from revolving credit facility, net of original issue discount98,000
Financing activitiesProceeds from long-term debt, net of original issue discount196,000
Financing activitiesPayment of deferred financing fees-226-958
Financing activitiesNet cash (used in) provided by financing activities-271293,042
Financing activitiesEffect of foreign exchange rates on cash28-109
Financing activitiesNet decrease in Cash, Cash Equivalents and Restricted Cash-83,587-188,509
Financing activitiesCash, cash equivalents and restricted cash, beginning of period609,451341,835
Financing activitiesCash, cash equivalents and restricted cash, end of period525,864153,326
Cash, Cash Equivalents and Restricted Cash are Comprised of:Cash and cash equivalents521,170151,603
Cash, Cash Equivalents and Restricted Cash are Comprised of:Restricted cash and cash equivalents4,6941,723
Cash, Cash Equivalents and Restricted Cash are Comprised of:Total cash, cash equivalents and restricted cash525,864153,326
Supplemental disclosure of cash flow informationCash paid during the year for interest9,32210,849
Supplemental disclosure of cash flow informationCash (received from) paid for income taxes-56$—
Supplemental disclosure of noncash investing and financing activitiesPurchases of property and equipment, accrued but not paid4,5927,003
Supplemental disclosure of noncash investing and financing activitiesRedemption of convertible promissory note9,3937,060
Supplemental disclosure of noncash investing and financing activitiesCapitalized software costs, accrued but not yet paid2,129$—
Supplemental disclosure of noncash investing and financing activitiesDeferred offering costs, accrued but not yet paid100$—
Supplemental disclosure of noncash investing and financing activitiesClass A Common Stock issued in connection with business combinations$—310,320
Supplemental disclosure of noncash investing and financing activitiesConvertible promissory note principal reset due to amendment$—72,488
Full release

Forward Looking Statements... (truncated)ed in this press release are forward-looking statements, including, but not limited to, Tempus’ expected financial results for full year 2026; expectations concerning Tempus' collaborations and partnerships; and Tempus' growth expectations. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including Tempus’ ability to realize the expected benefits of the acquisition of Paige AI, Ambry Genetics and Deep 6 AI; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, trade tensions and tariffs, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“the SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC from time to time. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

Contacts

Tempus Communications

Hanah Heintzelman media@tempus.com

Tempus Investor Relations

Elizabeth Krutoholow

Elizabeth.krutoholow@tempus.com

Source: Tempus AI, Inc.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Tempus AI earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.